Article
A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer.
Oncology - 1 Jan 2018
Park Cheol-Kyu, Oh In-Jae, Choi Yoo-Duk, Jang Tae-Won, Lee Jeong-Eun, Ryu Jeong-Seon, Lee Shin-Yup, Kim Young-Chul
Abstract excerpt
OBJECTIVES: We aimed to evaluate the prevalence and predictive role of c-MET expression and EGFR mutation in the efficacy of erlotinib in non-small-cell lung cancer (NSCLC). METHODS: We prospectively recruited 196 patients with stage IV or recurrent NSCLC treated with erlotinib after failure of first-line chemotherapy. Immunohistochemistry was used to evaluate c-MET overexpression, silver in situ hybridization...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.